Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolios

Masimo shares plunge 26% after Q2 warning; Stifel downgrades

Published 07/18/2023, 05:52 AM
© Reuters.  Masimo shares plunge 24% following disappointing preliminary Q2 results
MASI
-

Masimo Corporation (NASDAQ:MASI) stock plummeted more than 26% in pre-open Tuesday following the company’s preliminary Q2 revenue results.

The company sees Q2 revenues in the range of $453-$457 million, below the consensus estimate of $553.23M, with healthcare revenue of $280-$282M and non-healthcare revenue of $173-$175M.

Due to lower Q2 revenues, the company plans to cut costs in H2/23. More details will be shared with the complete Q2 financial results on August 8, 2023. Updated guidance for fiscal year 2023 will be provided on the same day.

Management plans to reduce the lower end of healthcare revenue guidance to $1.30 billion from $1.45B for the full year.

“We are still evaluating the upper end of revenue guidance for the healthcare business, but it could be materially higher than the lower end of the range, as we are still targeting our original guidance,” added the company.

Additionally, management anticipates reducing annual revenue guidance for the non-healthcare business to $800-$850M from $965-$995M.

Piper Sandler analysts discussed the above-mentioned issues that impacted the Q2 performance.

"Some of these are transitory and not concerning from a long-term perspective (shift in large order timing, hospital census below expectations), whereas others appear potentially more problematic for at least the intermediate term (elevated channel inventory levels tied to discounting, product availability challenges from OEM partners)," they said in a note.

Stifel analysts cut the rating to Hold from Buy and lowered the price target by $85 to $120 per share.

"While it’s clear Masimo’s long-term Healthcare fundamentals are intact, the Consumer outlook seems more uncertain. Over time, we expect the company will successfully adapt to these pressures and work through them helped by a healthy innovation pipeline and substantial contract backlog ($1.3B-$1.4B), but given the many moving pieces, it's difficult for us to feel our usual confidence in Masimo's near-to-medium term outlook," they wrote in a downgrade note.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Additional reporting by Senad Karaahmetovic

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.